Introduction
Dapagliflozin (marketed as FARXIGA ® in the US and FORXIGA ® in the EU and Russia) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor which decreases plasma glucose levels by suppressing renal glucose reabsorption from urine in the tubular system of the kidney, thereby increasing urinary glucose excretion. SGLT2 is preferentially expressed in the kidney and its inhibition by dapagliflozin leads to insulin-independent urinary glucose excretion, resulting in long-term improved glycaemic control evidenced by lowering of circulating haemoglobin A1c (HbA1c). Other beneficial effects include weight loss due to urinary caloric loss and decrease of blood pressure. Dapagliflozin shows a high level of selectivity for SGLT2 over other SGLT family members, no off-target effects, good oral bioavailability and a favourable safety profile in both animals and humans (Reilly et al., 2014) . Dapagliflozin is not genotoxic nor carcinogenic, based on results from batteries of in vitro and in vivo genotoxicity and 2-year carcinogenicity studies. In carcinogenicity studies in rats and mice, dapagliflozin did not induce tumours or hyperplasia in any tissues in either rodent species at any of the doses evaluated. The high doses in mice achieved exposures (based on area under the curve, AUC) that were 72 times (males) and 105 times (females) higher than human exposures (AUC) at the clinical dose of 10 mg per day. In rats, the high dose achieved exposures (AUC) that were approximately 131 times (males) and 186 times (females) higher than human exposure (AUC) at 10 mg (Reilly et al., 2014) .
In clinical studies conducted for regulatory approvals, there was an increased incidence of bladder tumours in cohorts treated with dapagliflozin as compared to placebo controls. Across 22 clinical studies, newly diagnosed cases of bladder cancer were reported in 10/6045 patients (0.17%) treated with dapagliflozin and 1/3512 patient (0.03%) treated with placebo/comparator. After excluding patients in whom exposure to study drug was less than 1 year at the time of diagnosis of bladder cancer, there were 4 cases with dapagliflozin and no cases with placebo/comparator. There were too few cases to determine whether the emergence of these events is related to dapagliflozin (Farxiga label; https://doi.org/10.1016/j.yrtph.2019.01.031 Received 24 August 2018; Received in revised form 18 January 2019; Accepted 23 January 2019 Ptaszynska et al., 2015) .
Regulators have expressed concern about if dapagliflozin may act like a bladder cancer promoter or progressor. We thus conducted a study in a 2-stage model of urinary bladder carcinogenesis in rats, to explore if this model could be used to see if drugs can affect tumour promotion and/or progression (Tirmenstein et al., 2018) . For a tumour initiator, we opted to use the N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) rat model, which is well established in the literature (Fukushima et al., 1982) and has been shown to be a good platform to explore promotion of bladder cancer by different mechanisms (Hicks, 1983; Ito and Fukushima, 1989) . The model consistently demonstrates pre-neoplastic and neoplastic urinary bladder lesions with a morphologic phenotype and biologic behaviour similar to what is observed in human transitional cell carcinoma (Vasconcelos-Nóbrega et al., 2012) . In our exploratory study (Tirmenstein et al., 2018) , rats were pre-treated for 6 weeks with BBN, and then for 26 weeks with 3 agents which have been ascribed tumour promoting effects; ascorbic acid (Fukushima et al., 1988) , rosiglitazone (Lubet et al., 2008) and uracil (Shirai et al., 1987) . The objectives of the exploratory study were to validate the model and to identify the most effective promoter, which under the specific conditions turned out to be uracil. Ascorbic acid did not have any promoter effect in the study, which illustrates the importance of performing exploratory studies even on well-established tumour models, as outcomes can vary significantly depending on the selected rodent strain, gender, dosing regimen, diet and other factors. Based on the results from the exploratory study, the present study was conducted to assess the bladder tumour promotion potential of dapagliflozin, using the same model and 3% uracil as a positive control.
Material and methods

Chemicals and formulations
N-Butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) was purchased from Tokyo Chemistry Industry Co., LTD, Tokyo, Japan. Uracil was obtained from Santa Cruz Biotechnology Inc., Dallas, TX, USA. N-Butyl-N-(4-hydroxybutyl)-nitrosamine dosing formulations were prepared by diluting BBN in a vehicle of 20% ethanol: 80% water to the appropriate concentrations to meet dose level requirements. The vehicle (20% ethanol: 80% water) was prepared weekly and stored at 4°C. The BBN dose formulations were prepared immediately prior to dosing and stirred continuously during dosing procedures. Dapagliflozin was formulated at 0.125 mg/mL in 90% polyethylene glycol 400 (PEG 400) in water (v/v) once weekly and stored at 4°C before use. Uracil (3%) diets were prepared weekly by adding sodium ascorbate and uracil at the indicated concentrations to Harlan Diet #2018C: Certified 18% Protein Diet.
Concentrations of the BBN formulations were analysed and found to be within ≤20% of each other; the mean concentration results were within 15% of theoretical concentration. The formulation of uracil was tested for concentration and homogeneity, and the results of all individual samples were ≤20% of each other; the mean concentration results within 15% of theoretical concentration. The formulated solutions for dapagliflozin were checked for concentration and stability during the intended duration of use. The results of all individual samples were ≤15% of each other and the mean concentration results were within ± 10% of the theoretical value. Absence of test item (i.e., 0 mg/ mL) was confirmed for the control group vehicle solutions.
Animals
Male Harlan Sprague-Dawley rats were obtained from Harlan Laboratories Inc., Indianapolis, IN, USA. A total of 280 animals were ordered. At the start of dosing, male rats were 5-6 weeks old and weighed between 131 and 197 g. Rats were housed in groups of 2-3 rats per cage in polycarbonate/polypropylene cages containing hiding tube and chewing object on corn cob bedding (Bed-o'Cobs; The Anderson Lab Bedding Inc.). Animal room temperatures were maintained at temperatures of 19°C-25°C and humidity at 30%-70%. Animal rooms were on a 12 h light/dark cycle. All rats had free access to water during the studies, and unless otherwise indicated, were fed Harlan Diet #2018C: Certified 18% Protein Diet ad libitum.
The Studies were conducted at Charles River Laboratories (CRL), Senneville, Quebec, Canada. All studies were conducted in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited facility and in accordance with the guidelines of the USA National Research Council and the Canadian Council on Animal Care. All animal care and study procedures were approved by the CRL Institutional Animal Care and Use Committee prior to study conduct.
Study design
Male Sprague-Dawley rats were used in the present study because male rats have been shown to be susceptible to BBN-induced bladder tumours in the previously conducted BBN range finding study (Tirmenstein et al., 2018) .
The study comprised of two phases: a 6-week initiation phase (Phase 1) during which rats were given BBN, followed by 2 weeks wash out, and a 26-week promotion phase (Phase 2) during which rats were given vehicle, dapagliflozin or positive control (uracil) (see Fig. 1 ).
In Phase 1 of the study, 165 male Sprague-Dawley rats were administered low dose BBN (100 mg/kg, po) and 115 male rats were administered high dose BBN (400 mg/kg, po) twice weekly for 6 weeks. During the 2-week wash-out period, a urinalysis was conducted during Week 7 (i e just after completion of phase 1 of the study) to assess the condition of the urinary bladder in these rats. To eliminate rats with potential renal/urinary bladder injuries, any rats with haematuria (as diagnosed by a positive dipstick test or by microscopic evaluation of urine sediment). Five animals in group 1 and two animals in group 2 had either large amount of blood in urine (scale used was negative, trace, small, moderate, large) or urine protein concentration of ≥3.0 g/ L and were not assigned to Phase 2 groups.
For Phase 2 of the study (Figs. 1) , 150 of the low dose BBN-treated rats were divided into 3 groups of 50 rats per group, with each group receiving one of the following treatments for 26 weeks:
Group 3: Control (vehicle of dapagliflozin, 90% PEG-400, po, at 4 mL/kg/day) Group 4: Dapagliflozin (0.5 mg/kg/day, po, at 4 mL/kg/ day); referred to as BBN100/dapagliflozin group in the result section Group 5: Uracil (3% in diet, ad libitum).
In addition, 100 of the high dose BBN-treated rats were divided into two groups of 50 rats per group, with each group receiving the following treatments for 26 weeks:
Group 6: Control (vehicle of dapagliflozin, 90% PEG-400, po, at 4 mL/kg/day) Group 7: Dapagliflozin (0.5 mg/kg/day, po, at 4 mL/kg/ day); referred to as BBN400/dapagliflozin group in result section.
The sample size for the study groups was powered to explore the hypotheses of interest with respect to comparing tumour incidences between groups. Total tumour incidence is the number of animals with a transitional cell carcinoma (TCC) within each group, as a proportion of the total number of animals within the group. Fifty animals per group gives at least 80% power to detect a difference between groups of 30% based on use of a one-sided Fisher's Exact Test for each set of comparisons. Specifically, if TCC incidences match those observed in the pilot study (Tirmenstein et al., 2018) , with a 13% incidence, a difference of 26% can be detected between groups. At the higher dose level (BBN 400 mg/kg, 67% TCC incidence), a difference of 24% can be detected between groups, with 40 animals per group. For this study, an increased pre-terminal loss is expected based on a previous study with uracil. Therefore, 50 animals per group was considered appropriate for this study. Based on observations in the pilot study, no positive promoter control group was added for high-dose BBN-treated rats, as this was predicted to lead to an unacceptable number of animals lost during the study.
Dose justification
The BBN doses used in Phase 1 of this study were selected based on a previous dose-ranging study (Tirmenstein et al., 2018) , where the dose response for the incidences of proliferative urothelial lesions was established. The oral route of administration of BBN to ensure that the exact dose was received by each animal, especially since they were group housed. The doses used in this study were expected to induce sufficient numbers of urinary bladder tumours in male rats to allow for a robust evaluation of the effects of dapagliflozin on promoting tumour development and progression.
In rat, an oral dose of dapagliflozin of 0.1 mg/kg pharmacologically increased the 24-h urinary glucose excretion above baseline at a systemic exposure like those in humans given the maximum recommended human therapeutic dose of 10 mg. Higher doses is associated with both increases in urinary glucose excretion associated with decreases in body-weight gains, and a potential for exaggeration of chronic progressive nephropathy, a common background in Sprague-Dawley rats (Reilly et al., 2014; Baylis and Corman, 1998) . For this study, a dapagliflozin dose of 0.5 mg/kg/day was expected to induce a pharmacological effect on urinary parameters without other adverse effects and provide an exposure margin approximately 7-fold of the exposure in humans given 10 mg (AUC of 0.465 μg h/mL in man; Reilly et al., 2014) .
Parameters assessed 2.4.1. Clinical observations
Mortality/moribundity checks were performed twice daily. Cage side observations were performed daily and detailed clinical observations including mass palpation were recorded at least once weekly. Veterinary examinations were performed once before treatment and as needed throughout the study. Individual rat bodyweights and food consumption were measured once weekly.
Urinalysis
Urine samples were collected during the wash-out period (study week 7), at start of phase 2 (study week 8) and during the last week of Phase 2 (study week 33). Urine was collected at room temperature from all rats placed individually in metabolism cages overnight. Rats were deprived of food but not water during the urine collection procedure. Urine samples were collected overnight in a container cooled on wet ice and stored refrigerated (set to maintain 4°C) until analysis. Urine was evaluated for colour, appearance, specific gravity, urinary sediment, protein, blood, bilirubin, ketones, pH, osmolality and total volume. Urine chemistry measurements included creatinine, glucose, and sodium.
Drug exposure
Blood samples were collected from the lateral tail vein from ten animals from each group in Phase 2. The samples were collected during Weeks 11 and 33 (Weeks 4 and 26 of Phase 2). For animals dosed with either vehicle or dapagliflozin, the time points for blood sampling were 0.5, 1, 2, 4, 8, and 24 h post dose (5 samples at each time point). For animals dosed with uracil in the diet, blood sampling was performed at 1-2 h following the end of the dark cycle. All samples were then analysed for plasma concentration of dapagliflozin and its metabolite dapagliflozin-3-O-glucuronide. Toxicokinetic parameters were estimated using WinNonlin pharmacokinetic software. A non-compartmental approach consistent with the oral route of administration was used for parameter estimation of t max , C max and AUC.
Pathology
All rats that survived to their scheduled necropsies or removed for humane reasons were euthanatized by isoflurane anaesthesia and subsequent exsanguination via the abdominal aorta. All animals were subject to gross examination and collection of the urinary bladder, which was weighed after emptying of urine, and preserved in 10% neutral buffered formalin as detailed below. No other tissues were collected.
After emptying the urine, a ligature was placed on the neck near the origin of the urethra and the bladder was removed after cutting distal to the ligature. The collected urinary bladders were gently infused with 10% neutral buffered formalin, which was injected from a syringe through a narrow-gauge needle at the ligature site, in the urinary bladder wall. The entire urinary bladders were then immersed in 10% formalin with ligature in place to maintain optimal inflation during fixation. Prior to embedding, urinary bladders were bisected transversely into two approximately equal halves. Both halves were embedded in one block so that initial sections were obtained from the cut surface. Urinary bladder blocks were then step-sectioned at approximately 0.5 mm intervals through the entire block for Hematoxylin & Eosin Fig. 1 . Overview of study design. Male rates were allocated to group 1 and 2, respectively, and treated as indicated. The number olf animals in each group are indicated (n). Following a washout, animals form group 2 were reallocated to groups 3, 4 and 5, while animals from group 2 were allocated to groups 6 and 7. During phase 2, animals were treated as indicated until end of the study. staining so that 6 to 10 slides (each with 2 sections of urinary bladder) were obtained. Histopathological evaluation of urinary bladder was performed by a board-certified veterinary pathologist (A.B.). Findings were subject to peer review by a second pathologist (M.S.).
For grading of urothelial lesions, the standard INHAND nomenclature for rodent studies (Frazier et al., 2012 ) was used as a basis. To capture the features of neoplastic progression from transitional cell/ urothelial papilloma to transitional cell/urothelial carcinoma in more detail, a definition from grading of human transitional cell carcinoma was selected (Cheng et al., 2012) . Briefly, a tumour with cytological atypia and urothelial thickness of > 7 cell layers was defined as a TCC. Representative images of the lesions observed are presented in Fig. 2. 
Analysis of data
All statistical tests were performed at the 5% significance level and the group pairwise comparisons of interest listed below were conducted as two-sided. Where data were collected at repeated time points, each time point was analysed separately. The following group pairwise comparisons were made: 1) dapagliflozin vs. control following BBN 100 mg/kg pre-treatment (Group 4 vs. Group 3); 2) dapagliflozin vs. control following BBN 400 mg/kg pre-treatment (Group 7 vs. Group 6); 3) control following BBN 400 mg/kg pre-treatment vs. control following BBN 100 mg/kg pre-treatment (Group 6 vs. Group 3) and 4) uracil vs. control following BBN 100 mg/kg pre-treatment (Group 5 vs. Group 3). To test the difference in total TCC tumour incidences between groups, Fisher's Exact test was used to conduct the group pairwise comparisons listed above.
Body and absolute bladder weights were analysed using a parametric ANOVA. Whenever the overall group effect was significant, the pairwise comparisons listed above were made using Student's t-test. Adjustments for multiplicity of tests were made based on the square root of the number of pairwise comparisons. For statistics, SRS (a CRL in-house application built with SAS) was used for analysis of incidence of TCC and CRL in-house reporting software Nevis (using SAS) was used for organ weight data.
Urine chemistry and selected Urine analysis data were analysed using a Kruskal-Wallis non-parametric ANOVA. Whenever the overall group effect was significant, the pairwise comparisons listed above were made using Wilcoxon Rank-Sum test. Adjustments for multiplicity of tests were made based on the square root of the number of pairwise comparisons.
Results
Drug exposure
No dapagliflozin or its metabolite, dapagliflozin-3-O-glucuronide, was detected in control animals. All animals dosed with dapagliflozin were exposed to dapagliflozin. The C max and AUC (0-24) of dapagliflozin were similar between Weeks 4 and 26 for either group of rats treated with 100 or 400 mg/kg BBN. Exposures of dapagliflozin were also similar between the two BBN groups on either Week 4 or Week 26. No quantifiable levels of dapagliflozin-3-O-glucuronide were detected and the toxicokinetics was only evaluated for dapagliflozin, which is shown in Table 1 .
In life observations
Phase 1
In Phase 1, one animal from the 400 mg/kg BBN group was removed from the study after dosing for 33 days, due to overall poor condition. Upon necropsy, there were no pathological findings considered Fig. 2 . Typical examples of histopathological lesions. A. Urothelial hyperplasia (arrowhead) and papilloma (arrow). Low magnification. Scale bar represents 500 μm. B. Urothelial hyperplasia. High magnification. Scale bar represents 100 μm. C. Transitional cell carcinoma in situ (arrowhead) and normal urothelium (arrow). Low magnification. Scale bar represents 3 mm. D. Normal urothelium. High magnification of area indicated in Fig. 2C . Scale bar represents 100 μm. E. Transitional cell carcinoma in situ. High magnification of area indicated in Fig. 2C . Scale bar represents 100 μm. F. Markedly invasive transitional cell carcinoma. Tumour growth into bladder lumen (arrowhead) and into surrounding adipose tissue (arrow). Low magnification. Scale bar represents 3 mm. G. Markedly invasive transitional cell carcinoma. High magnification. Scale bar represents 100 μm. Regulatory Toxicology and Pharmacology 103 (2019) 166-173 contributory to the condition of this animal (Table 2 ). One animal from the 100 mg/kg BBN group had red urine, possibly blood, after 27 days of dosing with BBN. There were no other noteworthy clinical observations during Phase 1. No body weight or food consumption effects were observed with BBN treatment.
Phase 2
In Phase 2, one animal treated with 400 mg/kg BBN during phase 1 and vehicle in phase 2 (Group 6) died on Day 103 of study (Table 2) . No cause of death was determined microscopically. Soft faeces and red fur staining, most likely due to the vehicle (90% PEG 400) were observed in the control group; similar clinical signs were present at similar incidences in the dapagliflozin groups which received dapagliflozin formulated in 90% PEG 400.
For animals treated with dapagliflozin, three animals from Group 4 (previously treated with 100 mg/kg BBN), died prior to scheduled termination; however, there were no pathological findings considered contributory to the death of any animal. Two animals from Group 7 (previously treated with 400 mg/kg BBN) died prior to scheduled termination; the death of one animal was attributed to urinary bladder infection whereas the cause of death for the other was not determined grossly or microscopically (Table 2 ). There was an increased incidence of yellow fur staining, dry skin and skin scabs in these animals when compared to the respective controls.
Mean food consumption was increased and lower mean body weight gains were noted in animals given dapagliflozin when compared to concurrent controls (Fig. 3) . By the end of Phase 2, the mean body weights of animals assigned to the dapagliflozin dose groups were approximately 4% and 6% lower than animals given vehicle only, for animals previously treated with BBN at 100 and 400 mg/kg, respectively (Table 4) .
Urinalysis
At Week 8 urinalysis, which established the baseline values for Phase 2, there were no significant differences in urinary volume, specific gravity, osmolarity or urine chemistry among the 5 groups of animals assigned to receive vehicle, dapagliflozin or uracil (data not shown).
At Week 33 of study, i.e., Week 26 of Phase 2, dosing with dapagliflozin (for animals previously treated with BBN at 100 or 400 mg/ kg/dose) resulted in increases in urine volume (up to 1.97X), total glucose excretion (up to 803X), glucose/creatinine ratio (up to 730X), total sodium excretion (up to 1.43X) and sodium/creatinine ratio (up to 1.33X). These effects are consistent with the pharmacologic effect of dapagliflozin. Removed early due to overall poor condition. Clinical observations prior to necropsy included: decreased activity, hunched posture and suspected dehydration. There were no pathological findings considered contributory to the death. Group 4: Dosed with dapagliflozin during phase 2 2 Found dead in its cage. Prior to death red fur staining was noted on the head, muzzle, and the lower jaw. There were no pathological findings considered contributory to the death. Group 6: Dosed with vehicle during phase 2 1 Found dead in its cage. Symptoms as above Group 7: Dosed with dapagliflozin during phase 2 1 Found dead in its cage. Prior to death, the clinical observations noted included urogenital brown fur staining, red fur staining (head, fore limbs, lower jaw, and muzzle), and abdominal yellow fur staining. A urinary infection was considered the likely cause of death. Group 7: Dosed with dapagliflozin during phase 2 1 Found dead in its cage. Prior to death, the clinical observations noted included red fur staining (head, back, lower jaw, and muzzle) and abdominal yellow fur staining. There were no pathological findings considered contributory to the death.
Overall number of animals removed or found dead in the study was 1 of 165 in group 2; 3 of 50 in group 4; 1 of 50 in group 6; and 2 of 50 in group 7. An increased incidence (44-50% of animals) of urine samples with positive blood and/or the presence of red blood cells was noted in control and dapagliflozin animals previously dosed with 400 mg/kg of BBN.
In the uracil group, there were increases in urine volume (3.66X), total sodium excretion (2.63X) and sodium/creatinine ratio (2.31X). In addition, total glucose excretion (3.13X) and glucose/creatinine ratio (2.69X) were increased but the increases were considerably less than those in animals given BBN/dapagliflozin. The group mean specific gravity and osmolarity were significantly decreased and 96% of animals in the group had haematuria (urine samples with positive blood and/or the presence of red blood cells).
A summary of the urinalysis results for Week 33 is shown in Table 3 .
Urinary bladder pathology
Organ weights
No dapagliflozin-related urinary bladder weight changes were noted. Statistically significant increases (3.5X vs. control) in urinary bladder weights were noted in animals administered 3% uracil (Group 5). An overview of bladder weight is shown in Table 4 . Fig. 3 . Food consumption (A) and body weight (B) during treatment in study phase 2. Groups 3 (closed circles) and 6 (open circles) were treated with vehicle (90% polyethylene glycol 400 in water by oral gavage). Groups 4 (filled squares) and 7 (open squares) were treated with dapagliflozin (0.5 mg/kg/day by oral gavage). Group 5 were treated with uracil (as a 3% diet admixture). Prior to treatment in phase 2, animals were pre-treated with N-Butyl-N-(4-hydroxybutyl)-nitrosamine twice weekly by oral gavage for 6 weeks at 100 mg/kg (groups 3, 4 and 5) or 400 mg/ kg (groups 6 and 7), then followed by a 2-week washout before the onset of study phase 2 (denoted as week 0 in the figure). 3.4.2. Histopathology A higher incidence of papilloma and carcinomas and higher incidence and severity of urothelial hyperplasia were noted at 400 mg/kg BBN in comparison to BBN 100 mg/kg, suggesting a dose-related effect of BBN. The higher incidence of carcinomas was statistically significant when comparing 400 mg/kg BBN to 100 mg/kg BBN (Group 6 to Group 3).
No carcinomas were observed in the BBN 100/vehicle or BBN 100/ dapagliflozin groups. In the BBN 100/uracil group a statistically significant increased incidence of in situ and microinvasive carcinomas was observed. Also, an increased severity of microscopic urothelial hyperplasia was seen in this group.
A slightly higher incidence of urothelial hyperplasia was noted in the BBN 100/dapagliflozin group (Group 4), in comparison to its respective control (Group 3). This observation was not statistically significant.
Markedly invasive carcinomas appeared in the BBN 400 mg/kg groups (Groups 6 and 7) while these advanced lesions were absent in the BBN 100 mg/kg groups (Groups 3, 4 and 5). There were no statistically significant differences in the incidences of in situ, minimally invasive or markedly invasive TCC between the BBN 400/vehicle and BBN 400/dapagliflozin groups (Groups 6 and 7).
A summary of the histopathological findings is shown in Table 5 .
Discussion
To address regulatory concern that dapagliflozin and/or hyperglycosuria may act as bladder cancer promoters/progressors, we tested this hypothesis in a 2-stage bladder tumour promotion model in rats with BBN as the initiator. This model is considered appropriate to assess the human risk because BBN is a urinary bladder-selective carcinogen in rodents, plus, the anatomic site and cellular environment of rodent bladders closely resembles conditions found in humans (VasconcelosNóbrega et al., 2012) . Also, rats are pharmacologically responsive to dapagliflozin. The dose of dapagliflozin selected for this study caused glucosuria but no other adverse effects, which allowed us to determine if glucosuria can impact the progression of bladder cancer initiated by BBN. The exposure levels were consistent with previous studies in rat (Obermeier et al., 2010; Reilly et al., 2014) . Contributing effects from dapagliflozin per se could also be explored as exposure was 7-fold human AUC.
Results from this study are consistent with results from our previous investigations on selection of promoters, in which 3% uracil treatment for 26 weeks preceded by BBN (100 mg/kg, 2x/week) for 6 weeks induced a papilloma incidence of 90% and a TCC incidence of 74% (Tirmenstein et al., 2018) . In the present study, uracil treatment induced a papilloma incidence of 82% and a TCC incidence of 88%. The increases in group mean bladder weights were also similar between the two studies (3.3x of control in previous study vs 3.5 x of control in the current study). The consistency in uracil responses between this study and the previous investigation demonstrates the reproducibility of our 2-stage model.
The pharmacological effects of dapagliflozin on food consumption, body weight gain and urinalysis parameters are also consistent with previous results in toxicology studies. The dose level of dapagliflozin gave systemic exposure more than that in patients given the maximum clinical dose and produced significant glycosuria in the rats. In the BBN 100 groups, treatment with dapagliflozin did not lead to development of carcinoma of any grade, while a diet with 3% uracil produced a significant increase of in situ and microinvasive TCC. These observations verify the capacity of uracil to act as a promoter of TCC, as well as the lack of promoter capacity of dapagliflozin and/or hyperglucosuria in this model of TCC. At higher exposures to BBN, BBN can act as both an initiator and promoter of TCC development, which is evidenced by the appearance of in situ and invasive TCC in the BBN 400/vehicle group. The absence of significant increases in the incidences of in situ, microinvasive and markedly invasive TCC in the BBN 400/dapagliflozin group demonstrates that dapagliflozin does not act as a tumour progressor in this study.
There is no obvious biological mechanism linking dapagliflozin to bladder cancer. The pharmacological target of dapagliflozin, SGLT2, is not expressed in the urinary bladder. In 9 dapagliflozin-treated patients with bladder cancer, 8 had microscopic haematuria prior to start of treatment or within 6 months of initiating study treatment (Ptaszynska et al., 2015) . It is therefore possible that the observed increase in bladder tumour incidence between treatment and placebo groups is due to an imbalance in pre-existing tumours. This is further also supported by the recent dapagliflozin outcomes trial DECLARE-TIMI 58, encompassing ca 17000 patients, in which a lower rate of bladder cancer with dapagliflozin than with placebo was observed (Wiviott et al., 2018) . Considering the lack of tumour findings in non-clinical studies as well as the short latency between first dapagliflozin exposure and tumour diagnosis in clinical trials, a causal relationship is considered unlikely. These new results add to evidence presented previously that dapagliflozin and glucosuria did not affect in vitro TCC proliferation rates and did not enhance tumour growth in nude mice heterotopically implanted with human bladder TCC cell lines, also showing that dapagliflozin does not act as a tumour promoter (Reilly et al., 2014) .
Conclusions
In a 2-stage bladder cancer model using BBN as an initiator, no statistically significant effects on the incidence or invasiveness of transitional cell carcinoma of the bladder were observed in rats pretreated with 100 or 400 mg/kg BBN for 6 weeks followed by 26 weeks of dapagliflozin treatment. These results show that dapagliflozin does not act as a promoter or progressor of bladder cancer in the presence of glucosuria.
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